Table 2.
BAL/serum cytokine concentrations in RSV infected mice treated with motavizumab compared with untreated RSV infected controls on day 5 after inoculation. Each group consisted of 4 samples randomly selected from two independent experiments.
| BAL (D5) | SERUM (D5) | |||||
| RSV Untreated | RSV Motavizumab | p value | RSV Untreated | RSV Motavizumab | p value | |
| IFN-γ | 1291.29 ± (561.3) | 640.84 ± (388.8) | 0.02 | 116.58 ± (43.1) | 28.29 ± * (35.7) | 0.02 |
| MCP-1 | 291.10 ± (128.6) | 132.0 ± (105.8) | 0.15 | 311.95 ± (78.3) | 343.26 ± (81.2) | 0.6 |
| RANTES | 118.82 ± (28.3) | 48.50 ± (51.9) | 0.055 | ND | ND | --- |
| IL-10 | 59.7 ± (52.91) | 25.68 ± (18.5) | 0.3 | 15.18 (10.0–71.9) | 23.28 (15.18–48.82) | 0.6 |
| TNF-α | 13.65 (10.32–17.35) | 10.0 (10.0–11.18) | 0.2 | ND | ND | --- |
| IL-12p70 | ND | ND | --- | 39.72 ± (20.6) | 38.07 ± (5.8) | 0.7 |
| IL-8 (KC) | 209.9 ± (88.8) | 117.75 ± (54.2) | 0.12 | 32.54 ± (27.96) | 25.82 ± (19.6) | 0.7 |
| IL-6 | 101.38 ± (51.22) | 30.46 ± (28.87) | 0.052 | ND | ND | ND |
| IL-1β | 34.63 ± (34.59) | 52.25 ± (54.3) | 0.6 | 180.66 ± (87.03) | 126.09 ± (58.3) | 0.4 |
| IL-1α | 12.59 ± (3.05) | 13.84 ± (3.7) | 0.6 | ND | ND | ND |
| IL-17 | ND | ND | --- | 13.02 (10.0–22.98) | 10.61 (10.0–11.77) | 0.5 |
Note: Data are shown as mean ± SD, or medians and 25–75% range as appropriate according to whether they were normally distributed. ND (non-detected).